1
|
Hohn M, Chang M, Meisel JE, Frost E, Schwegmann K, Hermann S, Schäfers M, Riemann B, Haufe G, Breyholz H, Wagner S. Synthesis and Preliminary In Vitroand In VivoEvaluation of Thiirane‐Based Slow‐Binding MMP Inhibitors as Potential Radiotracers for PET Imaging. ChemistrySelect 2018. [DOI: 10.1002/slct.201803093] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Affiliation(s)
- Michael Hohn
- Department of Nuclear MedicineUniversity Hospital Münster Albert-Schweitzer-Campus 1 Building A1 D-48149 Münster Germany
- Organic Chemistry InstituteUniversity of Münster Corrensstr. 40 D-48149 Münster Germany
| | - Mayland Chang
- Department of Chemistry and Biochemistry, 354 McCourtney HallUniversity of Notre Dame Notre Dame IN 46556–5710 USA
| | - Jayda E. Meisel
- Chemical, BiologicalRadiological, Nuclearand Explosive DefenseBattelle Memorial Institute 505 King Avenue Columbus Ohio 43201 USA
| | - Emma Frost
- Department of Chemistry and Biochemistry, 354 McCourtney HallUniversity of Notre Dame Notre Dame IN 46556–5710 USA
| | - Katrin Schwegmann
- European Institute for Molecular Imaging (EIMI)University of Münster Waldeyerstraße 15 D-48149 Münster Germany
| | - Sven Hermann
- European Institute for Molecular Imaging (EIMI)University of Münster Waldeyerstraße 15 D-48149 Münster Germany
| | - Michael Schäfers
- Department of Nuclear MedicineUniversity Hospital Münster Albert-Schweitzer-Campus 1 Building A1 D-48149 Münster Germany
- European Institute for Molecular Imaging (EIMI)University of Münster Waldeyerstraße 15 D-48149 Münster Germany
- Cells in Motion (CiM) Cluster of ExcellenceUniversity of Münster D-48149 Münster Germany
| | - Burkhard Riemann
- Department of Nuclear MedicineUniversity Hospital Münster Albert-Schweitzer-Campus 1 Building A1 D-48149 Münster Germany
| | - Günter Haufe
- Organic Chemistry InstituteUniversity of Münster Corrensstr. 40 D-48149 Münster Germany
- Cells in Motion (CiM) Cluster of ExcellenceUniversity of Münster D-48149 Münster Germany
| | - Hans‐Jörg Breyholz
- Department of Nuclear MedicineUniversity Hospital Münster Albert-Schweitzer-Campus 1 Building A1 D-48149 Münster Germany
| | - Stefan Wagner
- Department of Nuclear MedicineUniversity Hospital Münster Albert-Schweitzer-Campus 1 Building A1 D-48149 Münster Germany
| |
Collapse
|
2
|
Kniess T, Laube M, Brust P, Steinbach J. 2-[18F]Fluoroethyl tosylate – a versatile tool for building18F-based radiotracers for positron emission tomography. MEDCHEMCOMM 2015. [DOI: 10.1039/c5md00303b] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
The review highlights the role of 2-[18F]fluoroethyltosylate ([18F]FETs) in PET radiotracer design since it is a preferred labeling reagent according to its high reactivity to phenolic, amine, thiophenolic and carboxylic functions.
Collapse
Affiliation(s)
- Torsten Kniess
- Helmholtz-Zentrum Dresden-Rossendorf
- Institute of Radiopharmaceutical Cancer Research
- Dresden
- Germany
| | - Markus Laube
- Helmholtz-Zentrum Dresden-Rossendorf
- Institute of Radiopharmaceutical Cancer Research
- Dresden
- Germany
| | - Peter Brust
- Helmholtz-Zentrum Dresden-Rossendorf
- Institute of Radiopharmaceutical Cancer Research
- Dresden
- Germany
| | - Jörg Steinbach
- Helmholtz-Zentrum Dresden-Rossendorf
- Institute of Radiopharmaceutical Cancer Research
- Dresden
- Germany
| |
Collapse
|
3
|
Franck D, Kniess T, Steinbach J, Zitzmann-Kolbe S, Friebe M, Dinkelborg LM, Graham K. Investigations into the synthesis, radiofluorination and conjugation of a new [¹⁸F]fluorocyclobutyl prosthetic group and its in vitro stability using a tyrosine model system. Bioorg Med Chem 2012; 21:643-52. [PMID: 23290251 DOI: 10.1016/j.bmc.2012.11.049] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2012] [Revised: 11/12/2012] [Accepted: 11/29/2012] [Indexed: 11/29/2022]
Abstract
The [(18)F]fluorocyclobutyl group has the potential to be a metabolically stable prosthetic group for PET tracers. The synthesis of the radiolabeling precursor cis-cyclobutane-1,3-diyl bis(toluene-4-sulfonate) 8 was obtained from epibromohydrin in 7 steps (2% overall yield). The radiolabeling of this precursor 8 and its conjugation to L-tyrosine as a model system was successfully achieved to give the new non-natural amino acid 3-[(18)F]fluorocyclobutyl-L-tyrosine (L-3-[(18)F]FCBT) [(18)F]17 in 8% decay-corrected yield from the non-carrier-added [(18)F]fluoride. L-3-[(18)F]FCBT was investigated in vitro in different cancer cell lines to determine the uptake and stability. The tracer [(18)F]17 showed a time dependent uptake into different tumor cell lines (A549, NCI-H460, DU145) with the best uptake of 5.8% injected dose per 5×10(5) cells after 30min in human lung carcinoma cells A549. The stability of L-3-[(18)F]FCBT in human and rat plasma and the stability of the non-radioactive L-3-FCBT in rat hepatocytes were both found to be excellent. These results show that the non-natural amino acid L-3-[(18)F]FCBT is a promising metabolically stable radiotracer for positron emission tomography.
Collapse
Affiliation(s)
- Dominic Franck
- Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany
| | | | | | | | | | | | | |
Collapse
|
4
|
Radeke HS, Purohit A, Harris TD, Hanson K, Jones R, Hu C, Yalamanchili P, Hayes M, Yu M, Guaraldi M, Kagan M, Azure M, Cdebaca M, Robinson S, Casebier D. Synthesis and Cardiac Imaging of (18)F-Ligands Selective for β1-Adrenoreceptors. ACS Med Chem Lett 2011; 2:650-5. [PMID: 24900360 DOI: 10.1021/ml1002458] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2010] [Accepted: 07/22/2011] [Indexed: 11/27/2022] Open
Abstract
A series of potent and selective β1-adrenoreceptor ligands were identified (IC50 range, 0.04-0.25 nM; β1/β2 selectivity range, 65-450-fold), labeled with the PET radioisotope fluorine-18 and evaluated in normal Sprague-Dawley rats. Tissue distribution studies demonstrated uptake of each radiotracers from the blood pool into the myocardium (0.48-0.62% ID/g), lung (0.63-0.97% ID/g), and liver (1.03-1.14% ID/g). Dynamic μPET imaging confirmed the in vivo dissection studies.
Collapse
Affiliation(s)
- Heike S. Radeke
- Research and Development, Lantheus Medical Imaging, 331 Treble Cove Road, North Billerica, Massachusetts 01862, United States
| | - Ajay Purohit
- Research and Development, Lantheus Medical Imaging, 331 Treble Cove Road, North Billerica, Massachusetts 01862, United States
| | - Thomas D. Harris
- Research and Development, Lantheus Medical Imaging, 331 Treble Cove Road, North Billerica, Massachusetts 01862, United States
| | - Kelley Hanson
- Research and Development, Lantheus Medical Imaging, 331 Treble Cove Road, North Billerica, Massachusetts 01862, United States
| | - Reinaldo Jones
- Research and Development, Lantheus Medical Imaging, 331 Treble Cove Road, North Billerica, Massachusetts 01862, United States
| | - Carol Hu
- Research and Development, Lantheus Medical Imaging, 331 Treble Cove Road, North Billerica, Massachusetts 01862, United States
| | - Padmaja Yalamanchili
- Research and Development, Lantheus Medical Imaging, 331 Treble Cove Road, North Billerica, Massachusetts 01862, United States
| | - Megan Hayes
- Research and Development, Lantheus Medical Imaging, 331 Treble Cove Road, North Billerica, Massachusetts 01862, United States
| | - Ming Yu
- Research and Development, Lantheus Medical Imaging, 331 Treble Cove Road, North Billerica, Massachusetts 01862, United States
| | - Mary Guaraldi
- Research and Development, Lantheus Medical Imaging, 331 Treble Cove Road, North Billerica, Massachusetts 01862, United States
| | - Mikhail Kagan
- Research and Development, Lantheus Medical Imaging, 331 Treble Cove Road, North Billerica, Massachusetts 01862, United States
| | - Michael Azure
- Research and Development, Lantheus Medical Imaging, 331 Treble Cove Road, North Billerica, Massachusetts 01862, United States
| | - Michael Cdebaca
- Research and Development, Lantheus Medical Imaging, 331 Treble Cove Road, North Billerica, Massachusetts 01862, United States
| | - Simon Robinson
- Research and Development, Lantheus Medical Imaging, 331 Treble Cove Road, North Billerica, Massachusetts 01862, United States
| | - David Casebier
- Research and Development, Lantheus Medical Imaging, 331 Treble Cove Road, North Billerica, Massachusetts 01862, United States
| |
Collapse
|
5
|
Law MP, Wagner S, Kopka K, Renner C, Pike VW, Schober O, Schäfers M. Preclinical evaluation of an 18F-labelled beta1-adrenoceptor selective radioligand based on ICI 89,406. Nucl Med Biol 2010; 37:517-26. [PMID: 20447564 DOI: 10.1016/j.nucmedbio.2010.01.004] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2009] [Revised: 12/21/2009] [Accepted: 01/18/2010] [Indexed: 10/19/2022]
Abstract
PURPOSE Radioligand binding studies indicate a down-regulation of myocardial beta(1)-adrenoceptors (beta(1)-AR) in cardiac disease which may or may not be associated with a decrease in beta(2)-ARs. We have chosen ICI 89,406, a beta(1)-selective AR antagonist, as the lead structure to develop new beta(1)-AR radioligands for PET and have synthesised a fluoro-ethoxy derivative (F-ICI). METHODS (S)-N-[2-[3-(2-Cyano-phenoxy)-2-hydroxy-propylamino]-ethyl]-N'-[4-(2-[(18)F]fluoro-ethoxy)-phenyl]-urea ((S)-[(18)F]F-ICI) was synthesised. Myocardial uptake of radioactivity after intravenous injection of (S)-[(18)F]F-ICI into adult CD(1) mice or Wistar rats was assessed with positron emission tomography (PET) and postmortem dissection. Metabolism was assessed by high-performance liquid chromatography analysis of plasma and urine. RESULTS The heart was visualised with PET after injection of (S)-[(18)F]F-ICI but neither unlabelled F-ICI nor propranolol (non-selective beta-AR antagonist) injected 15 min after (S)-[(18)F]F-ICI affected myocardial radioactivity. Ex vivo dissection demonstrated that predosing with propranolol or CGP 20712 (beta(1)-selective AR-antagonist) did not affect myocardial radioactivity. Radiometabolites rapidly appeared in plasma and both (S)-[(18)F]F-ICI and radiometabolites accumulated in urine. CONCLUSIONS Myocardial uptake of (S)-[(18)F]F-ICI after intravenous injection was mainly at sites unrelated to beta(1)-ARs. (S)-[(18)F]F-ICI is not a suitable beta(1)-selective-AR radioligand for PET.
Collapse
Affiliation(s)
- Marilyn P Law
- Department of Nuclear Medicine, University Hospital Münster, D-48149 Münster, Germany.
| | | | | | | | | | | | | |
Collapse
|
6
|
Janssens K, Boussemaere M, Wagner S, Kopka K, Denef C. Beta1-adrenoceptors in rat anterior pituitary may be constitutively active. Inverse agonism of CGP 20712A on basal 3',5'-cyclic adenosine 5'-monophosphate levels. Endocrinology 2008; 149:2391-402. [PMID: 18202135 DOI: 10.1210/en.2007-1397] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Catecholamines directly stimulate GH, ACTH, and prolactin secretion from rat anterior pituitary through the beta(2)-adrenoceptor (AR). We recently showed that gonadotrophs express the beta(1)-AR and that glucocorticoids drastically increase its mRNA expression level. The present investigation explores whether beta(1)-ARs are functionally coupled to adenylate cyclase. In anterior pituitary cell aggregates, the highly selective beta(1)-AR antagonists CGP 20712A and ICI 89,406-8a attenuated isoproterenol-stimulated cAMP accumulation, but no agonist action of norepinephrine could be detected. Remarkably, CGP 20712A inhibited basal cAMP levels by its own for at least 50%, an action that tended to be more effective in dexamethasone-supplemented medium. The latter effect was abolished by the beta-AR antagonist carvedilol, but not by other beta-AR antagonists. Pretreatment with pertussis toxin abolished the action of CGP 20712A on basal cAMP. CGP 20712A also attenuated isoproterenol-induced cAMP accumulation in the gonadotroph cell lines alphaT3-1 and LbetaT2, but not in the somatotroph precursor cell line GHFT and the folliculo-stellate cell line TtT/GF. However, in LbetaT2 cells CGP 20712A did not inhibit basal cAMP levels by its own. The present data suggest that beta(1)-AR in the anterior pituitary is positively coupled to adenylyl cyclase but is constitutively active in a pertussis toxin-sensitive manner. CGP 20712A may act as an inverse agonist with approximately 50% negative intrinsic activity, suggesting that the beta(1)-AR significantly contributes to basal adenylate cyclase activity in the pituitary.
Collapse
Affiliation(s)
- Kristel Janssens
- Laboratory of Cell Pharmacology, University of Leuven, Medical School, Campus Gasthuisberg (O & N), B-3000 Leuven, Belgium
| | | | | | | | | |
Collapse
|
8
|
Law MP, Wagner S, Kopka K, Pike VW, Schober O, Schäfers M. Are [O-methyl-11C]derivatives of ICI 89,406 beta1-adrenoceptor selective radioligands suitable for PET? Eur J Nucl Med Mol Imaging 2007; 35:174-85. [PMID: 17906860 DOI: 10.1007/s00259-007-0553-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2007] [Accepted: 07/15/2007] [Indexed: 10/22/2022]
Abstract
PURPOSE Radioligand binding studies show that beta(1)-adrenoceptor (beta(1)-AR) density may be reduced in heart disease without down regulation of beta(2)-ARs. Radioligands are available for measuring total beta-AR density non-invasively with clinical positron emission tomography (PET) but none are selective for beta(1)- or beta(2)-ARs. The aim was to evaluate ICI 89,406, a beta(1)-AR-selective antagonist amenable to labelling with positron emitters, for PET. METHODS The S-enantiomer of an [O-methyl-(11)C] derivative of ICI 89,406 ((S)-[(11)C]ICI-OMe) was synthesised. Tissue radioactivity after i.v. injection of (S)-[(11)C]ICI-OMe (< 2 nmol x kg(-1)) into adult Wistar rats was assessed by small animal PET and post mortem dissection. Metabolism was assessed by HPLC of extracts prepared from plasma and tissues and by measuring [(11)C]CO(2) in exhaled air. RESULTS The heart was visualised by PET after injection of (S)-[(11)C]ICI-OMe but neither unlabelled (S)-ICI-OMe nor propranolol (non-selective beta-AR antagonist) injected 15 min after (S)-[(11)C]ICI-OMe affected myocardial radioactivity. Ex vivo dissection showed that injecting unlabelled (S)-ICI-OMe, propranolol or CGP 20712A (beta(1)-selective AR antagonist) at high dose (> 2 mumol x kg(-1)) before (S)-[(11)C]ICI-OMe had a small effect on myocardial radioactivity. HPLC demonstrated that radioactivity in myocardium was due to unmetabolised (S)-[(11)C]ICI-OMe although (11)C-labelled metabolites rapidly appeared in plasma and liver and [(11)C]CO(2) was detected in exhaled air. CONCLUSION Myocardial uptake of (S)-[(11)C]ICI-OMe after i.v. injection was low, possibly due to rapid metabolism in other tissues. Injection of unlabelled ligand or beta-AR antagonists had little effect indicating that binding was mainly to non-specific myocardial sites, thus precluding the use of (S)-[(11)C]ICI-OMe to assess beta(1)-ARs with PET.
Collapse
Affiliation(s)
- Marilyn P Law
- Department of Nuclear Medicine, University Hospital Münster, Albert-Schweitzer-Str. 33, 48149, Münster, Germany.
| | | | | | | | | | | |
Collapse
|
9
|
Stegger L, Schäfers K, Kopka K, Wagner S, Hermann S, Kies P, Law M, Schober O, Schäfers M. Molecular cardiovascular imaging using scintigraphic methods. Eur Radiol 2007; 17:1422-32. [PMID: 17206422 DOI: 10.1007/s00330-006-0541-6] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2006] [Revised: 11/02/2006] [Accepted: 11/24/2006] [Indexed: 10/23/2022]
Abstract
Molecular cardiovascular imaging plays an increasingly important role both in basic research and in clinical diagnosis. Scintigraphic methods have long been used to study pathophysiological changes on a cellular and molecular level, and they are likely to remain important molecular imaging modalities in the foreseeable future. This article provides an overview over current developments in cardiovascular molecular imaging using scintigraphic methods. The focus lies on imaging of cardiac innervation, plaque instability, hypoxia and angiogenesis, gene expression and stem and progenitor cell migration and proliferation.
Collapse
Affiliation(s)
- Lars Stegger
- Department of Nuclear Medicine, University Hospital of Münster, Albert-Schweitzer-Str. 33, 48149 Münster, Germany.
| | | | | | | | | | | | | | | | | |
Collapse
|